NCT07063212 - A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

January 2, 2028

Study Completion Date

January 2, 2028

Conditions

Squamous Cell Carcinoma of Head and NeckSinus CancerNasal Cavity CancerOral Cavity CancerOropharynx CancerHypopharynx CancerLarynx CancerOral Squamous Cell CarcinomaOropharynx Squamous Cell CarcinomaHypopharynx Squamous Cell CarcinomaLarynx Squamous Cell CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG

Sacituzumab Govitecan

Sacituzumab govitecan (SG; Trodelvy®) is a trophoblast cell-surface antigen 2 (Trop-2)- directed antibody-drug conjugate

DRUG

Cetuximab

Cetuximab (also known as ERBITUX®) is an epidermal growth factor receptor (EGFR) antagonist

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale